ASH 2022 | Cost-effectiveness of azacitidine and ivosidenib in elderly patients with newly diagnosed IDH1m AML
Jan Bewersdorf
• 11 Dec 2022
Jan Philipp Bewersdorf, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, shares the results of a study that evaluated the cost-effectiveness of the combination of azacitidine and ivosidenib in newly diagnosed older, intensive chemotherapy-ineligible patients. Despite the overall survival (OS) benefit demonstrated in the AGILE study (NCT03173248), the analysis found that this combination was not cost-effective in comparison to azacitidine monotherapy. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
